Professoriate Staff

Dr Ning WANG
Assistant Professor,
School of Chinese Medicine,
Li Ka Shing Faculty of Medicine,
The University of Hong Kong
  • School of Chinese Medicine, The University of Hong Kong, 10 Sassoon Road, Pokfulam, Hong Kong
  • (852) 3917 6441
  • (852) 2872 5476
  • ckwang@hku.hk
ACADEMIC QUALIFICATIONS
Sep. 2008 – Jun. 2012 The University of Hong Kong, Hong Kong S.A.R.
Awarded Doctor of Philosophy (Major in Pharmacology of Chinese herbal Medicine)
Sep. 2006 – Jul. 2008 Sun Yat-Sen University, Guangdong, China.
Awarded Master Degree in Science (Major in Pharmaceutical Science)
Sep. 2002 – Jul. 2006 Sun Yat-Sen University, Guangdong, China.
Awarded Bachelor Degree in Science
WORKING EXPERIENCE
Aug. 2018 – Present Assistant Professor in School of Chinese Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong S.A.R.
Aug. 2015 – July. 2018 Research Assistant Professor in School of Chinese Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong S.A.R.
May. 2014 – Jul. 2014 Visiting Research Fellow in Centre for Integrative Chinese Medicine, Faculty of Life Science and Medicine, King’s College London, United Kingdom
Jul. 2012 – Jul. 2015 Post-doctoral fellow in School of Chinese Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong S.A.R.
LANGUAGES SPOKEN & WRITTEN

English, Cantonese and Mandarin

AREAS OF EXPERTISE

Pharmacology of plant-based natural products

ACADEMIC AND PROFESSIONAL MEMBERSHIP

- European Association for Cancer Research (2012-)
- World Association of Chinese Medicine for Immunology (2014-)
- Hong Kong Association of Herbal Pharmacology (2017-)

TEACHING & RESEARCH AREA
Teaching subjects:





- Pharmacology of Chinese herbal medicine for Bachelor of Chinese Medicine and Bachelor of Pharmacy students
- Field Trip & Chinese Medicine Dispensary Practicum
- Chinese Materia Medica
- Research Progress of Pharmacology and Toxicology of Chinese herbal Medicines
- Medical Ethics and Professionalism in Chinese Medicine Practice
Research fields:


- Discovery of novel natural autophagy regulatory molecules from medicinal plants
- Discovery of natural anti-cancer drug lead from medicinal plants
- Discovery of natural compounds from medicinal plants for the treatment of metabolic disorders
PUBLICATIONS
A. Peer-reviewed Journal Articles (*corresponding author)
First/co-first or corresponding authorship
  1. Wang N, Tan HY (co-first author), Lu Y, Chan YT, Wang D, Guo W, Xu Y, Zhang C, Chen F, Tang G, Feng Y. PIWIL1 governs the crosstalk of cancer cell metabolism and immunosuppressive microenvironment in hepatocellular carcinoma. Signal Transduct Target Ther. Accepted for publication. (IF: 13.493)
  2. Qu Y, Tan HY, Chan YT, Jiang H, Wang N*, Wang D*. The functional role of long noncoding RNA in resistance to anticancer treatment. Ther Adv Med Oncol. 2020 Jun 1;12:1758835920927850. (IF: 6.852)
  3. Lu Y, Chan YT, Tan HY, Li S, Wang N*, Feng Y*. Epigenetic regulation in human cancer: the potential role of epi-drug in cancer therapy. Mol Cancer. 2020 Apr 27;19(1):79. (IF: 15.302)
  4. Tan HY, Wang N (co-first author), Chan YT, Zhang C, Guo W, Chen F, Zhong Z, Li S, Feng Y*. ID1 overexpression increases gefitinib sensitivity in non-small cell lung cancer by activating RIP3/MLKL-dependent necroptosis. Cancer Lett. 2020; 475:109-118. (IF:7.360)
  5. Wang N, Tan HY, Li S, Wang D, Xu Y, Zhang C, Xia W, Che CM, Feng Y*. Remission of Obesity-Induced Insulin Resistance via Modulating SBP2 Expression in Adipose Tissue Macrophages. Sci Adv, 2019, 5, eaav0198. (IF:13.116)
  6. Wang N, Zhang C, Xu Y, Li S, Tan HY, Xia W, Feng Y*. OMICs approaches-assisted identification of macrophages-derived MIP-1γ as the therapeutic target of botanical products TNTL in diabetic retinopathy. Cell Commun Signal. 2019; 17(1):81. (IF:4.344)
  7. Qu Y, Dou B, Tan H, Feng Y*, Wang N*, Wang D*. Tumor microenvironment-driven non-cell-autonomous resistance to antineoplastic treatment. Mol Cancer. 2019;18(1):69. (IF:15.302)
  8. Jiang X, Tan HY, Teng S, Chan YT, Wang D*, Wang N*. The Role of AMP-Activated Protein Kinase as a Potential Target of Treatment of Hepatocellular Carcinoma. Cancers (Basel). 2019;11(5). pii: E647. (IF:6.162)
  9. Wang N, Tan HY, Feng YG, Zhang C, Chen F, Feng Y*. microRNA-23a in Human Cancer: Its Roles, Mechanisms and Therapeutic Relevance. Cancers (Basel). 2018;11(1). pii: E7. (IF:6.126)
  10. Wang N, Tan HY, Li S, Feng Y*. Atg9b Deficiency Suppresses Autophagy and Potentiates Endoplasmic Reticulum Stress-Associated Hepatocyte Apoptosis in Hepatocarcinogenesis. Theranostics, 2017; 7:2325-38. (IF:8.579)
  11. Wang N, Tan HY, Li S, Xu Y, Guo W, Feng Y*. Supplementation of Micronutrient Selenium in Metabolic Diseases: Its Role as an Antioxidant. Oxid Med Cell Longev. 2017;2017:7478523. (IF:5.076)
  12. Lan J, Wang N (co-first author), Huang L, Liu Y, Ma X, Lou H, Chen C, Feng Y*, Pan W*. Design and synthesis of novel tetrandrine derivatives as potential anti-tumor agents against human hepatocellular carcinoma. Eur J Med Chem. 2017;127:554-66. (IF:5.572)
  13. Wang N, Tan HY, Chan YT, Guo W, Li S, Feng Y*. Identification of WT1 as determinant of heptatocellular carcinoma and its inhibition by Chinese herbal medicine Salvia chinensis Benth and its active ingredient protocatechualdehyde. Oncotarget. 2017;8(62):105848-59.
  14. Wang N, Wang X, Tan HY, Li S, Tsang CM, Tsao SW, Feng Y*. Berberine Suppresses Cyclin D1 Expression through Proteasomal Degradation in Human Hepatoma Cells. Int J Mol Sci. 2016;17. pii: E1899. (IF:4.556)
  15. Wang N, Xu Q, Tan HY, Hong M, Li S, Yuen MF, Feng Y. Berberine Inhibition of Fibrogenesis in a Rat Model of Liver Fibrosis and in Hepatic Stellate Cells. Evid Based Complement Alternat Med. 2016;2016:8762345. (IF:1.813)
  16. Tan HY, Wang N (co-first author), Man K, Tsao SW, Che CM, Feng Y*. Autophagy-induced RelB/p52 activation mediates tumour-associated macrophage repolarisation and suppression of hepatocellular carcinoma by natural compound baicalin. Cell Death Dis. 2015;6:e1942. (IF:6.304)
  17. Wang N, Tan HY, Li L, Yuen MF, Feng Y*. Berberine and Coptidis Rhizoma as potential anticancer agents: Recent updates and future perspectives. J Ethnopharmacol. 2015;176:35-48. (IF:3.690)
  18. Wang N, Feng Y*, Tan HY, Cheung F, Hong M, Lao L, Nagamatsu T. Inhibition of eukaryotic elongation factor-2 confers to tumor suppression by a herbal formulation Huanglian-Jiedu decoction in human hepatocellular carcinoma. J Ethnopharmacol. 2015;164:309-18. (IF: 3.690)
  19. Wang N, Feng Y, Cheung F, Wang X, Zhang Z, Feng Y. A Chinese medicine formula Gegen Qinlian decoction suppresses expansion of human renal carcinoma with inhibition of matrix metalloproteinase-2. Integr Cancer Ther. 2015;14:75-85. (IF:2.379)
  20. Wang N, Feng Y. Elaborating the role of natural products-induced autophagy in cancer treatment: achievements and artifacts in the state of the art. Biomed Res Int. 2015;2015:934207. (IF:2.276)
  21. Wang N, Zhu M, Wang X, Tan HY, Tsao SW, Feng Y*. Berberine-induced tumor suppressor p53 up-regulation gets involved in the regulatory network of MIR-23a in hepatocellular carcinoma. Biochim Biophys Acta. 2014;1839:849-57. (IF:3.510)
  22. Xu B, Wang N (co-first author), Pan W, Qiu J, Cao P, Zhu M, Feng Y*, Liang G*. Synthesis and anti-tumor activity evaluation of Matijin-Su derivatives. Bioorg Chem. 2014;56:34-40. (IF:4.831)
  23. Wang N, Zhu M, Tsao SW, Man K, Zhang Z, Feng Y*. MiR-23a-mediated inhibition of topoisomerase 1 expression potentiates cell response to etoposide in human hepatocellular carcinoma. Mol Cancer. 2013;12:119. (IF:15.302)
  24. Wang N, Feng Y*, Zhu M, Siu FM, Ng KM, Che CM. A novel mechanism of XIAP degradation induced by timosaponin AIII in hepatocellular carcinoma. Biochim Biophys Acta. 2013;1833:2890-9. (IF:4.105)
  25. Wang N, Zhu M, Tsao SW, Man K, Zhang Z, Feng Y. Up-regulation of TIMP-1 by genipin inhibits MMP-2 activities and suppresses the metastatic potential of human hepatocellular carcinoma. PLoS One. 2012;7:e46318. (IF:2.740)
  26. Wang N, Feng Y, Cheung F, Chow OY, Wang X, Su W, Tong Y. A comparative study on the hepatoprotective action of bear bile and Coptidis Rhizoma aqueous extract on experimental liver fibrosis in rats. BMC Complement Altern Med. 2012;12:239. (IF:2.833)
  27. Wang N, Pan W, Zhu M, Zhang M, Hao X, Liang G*, Feng Y*. Fangchinoline induces autophagic cell death via p53/sestrin2/AMPK signalling in human hepatocellular carcinoma cells. Br J Pharmacol. 2011;164:731-42. (IF:7.730)
  28. Wang N, Feng Y, Xie TN, Su W, Zhu M, Chow O, Zhang Y, Ng KM, Leung CH, Tong Y. Chemical and biological analysis of active free and conjugated bile acids in animal bile using HPLC-ELSD and MTT methods. Exp Ther Med. 2011; 2:125-30. (IF:1.785)
  29. Wang N, Feng Y*, Zhu M, Tsang CM, Man K, Tong Y, Tsao SW. Berberine induces autophagic cell death and mitochondrial apoptosis in liver cancer cells: the cellular mechanism. J Cell Biochem. 2010;111:1426-36. (IF:4.237)
  30. Wang N, Feng Y, Lau EP, Tsang C, Ching Y, Man K, Tong Y, Nagamatsu T, Su W, Tsao S. F-actin reorganization and inactivation of rho signaling pathway involved in the inhibitory effect of Coptidis Rhizoma on hepatoma cell migration. Integr Cancer Ther. 2010; 9:354-64. (IF:2.379)
  31. Wang N, Li P, Wang Y, Peng W, Wu Z, Tan S, Liang S, Shen X, Su W*. Hepatoprotective effect of Hypericum japonicum extract and its fractions. J Ethnopharmacol. 2008;116:1-6. (IF:3.690)
  32. Co-authorship

  33. Tan HY, Wang N, Zhang C, Chan YT, Yuen MF, Feng Y. LOXL4 Fosters an Immunosuppressive Microenvironment During Hepatocarcinogenesis. Hepatology. 2020 Oct 17. doi: 10.1002/hep.31600. (IF:14.679)
  34. Xu Y, Wang N, Tan HY, Li S, Zhang C, Zhang Z, Feng Y. Panax notoginseng saponins modulate the gut microbiota to promote thermogenesis and beige adipocyte reconstruction via leptin-mediated AMPKα/STAT3 signaling in diet-induced obesity. Theranostics. 2020 Sep 14;10(24):11302-11323. (IF:8.579)
  35. Li S, Wang N, Tan HY, Chueng F, Zhang ZJ, Yuen MF, Feng Y. Modulation of gut microbiota mediates berberine-induced expansion of immuno-suppressive cells to against alcoholic liver disease. Clin Transl Med. 2020 Aug;10(4):e112. (IF:7.919)
  36. Li L, Tam CW, Wang N, Cheung F, Zhou Q, Zhang C, Cheng CS, Xiong L, Feng Y. Effectiveness of blending E-learning with field trip on Chinese herbal medicine education: quasi-experimental study. BMC Complement Med Ther. 2020 Aug 10;20(1):248. (IF:2.833)
  37. Guo W, Tan HY, Li S, Wang N, Feng Y. Glutamic-Pyruvic Transaminase 1 Facilitates Alternative Fuels for Hepatocellular Carcinoma Growth-A Small Molecule Inhibitor, Berberine. Cancers (Basel). 2020 Jul 9;12(7):1854. (IF:6.126)
  38. Chen F, Zhong Z, Tan HY, Wang N, Feng Y. The Significance of Circulating Tumor Cells in Patients with Hepatocellular Carcinoma: Real-Time Monitoring and Moving Targets for Cancer Therapy. Cancers (Basel). 2020 Jun 29;12(7):1734. (IF:6.126)
  39. Wang X, Zeng J, Wang X, Li J, Chen J, Wang N, Zhang M, Feng Y, Guo H. 2,3,5,4'-tetrahydroxystilbene-2-O-β-D-glucoside induces autophagy of liver by activating PI3K/Akt and Erk pathway in prediabetic rats. BMC Complement Med Ther. 2020 Jun 8;20(1):177. (IF:2.833)
  40. Xu Y, Guo W, Zhang C, Chen F, Tan HY, Li S, Wang N, Feng Y. Herbal Medicine in the Treatment of Non-Alcoholic Fatty Liver Diseases-Efficacy, Action Mechanism, and Clinical Application. Front Pharmacol. 2020 May 12;11:601. (IF:4.225)
  41. Chan YT, Cheung F, Zhang C, Fu B, Tan HY, Norimoto H, Wang N, Feng Y. Ancient Chinese Medicine Herbal Formula Huanglian Jiedu Decoction as a Neoadjuvant Treatment of Chemotherapy by Improving Diarrhea and Tumor Response. Front Pharmacol. 2020 Mar 10;11:252. (IF:4.225)
  42. Zhang D, Li S, Wang N, Tan HY, Zhang Z, Feng Y. The Cross-Talk Between Gut Microbiota and Lungs in Common Lung Diseases. Front Microbiol. 2020 Feb 25;11:301. (IF:4.235)
  43. Xu Y, Wang N, Tan HY, Li S, Zhang C, Feng Y. Function of Akkermansia muciniphila in Obesity: Interactions With Lipid Metabolism, Immune Response and Gut Systems. Front Microbiol. 2020 Feb 21;11:219. (IF:4.235)
  44. Zhang C, Wang N, Tan HY, Guo W, Chen F, Zhong Z, Man K, Tsao SW, Lao L, Feng Y. Direct inhibition of TLR4/MyD88 pathway by geniposide suppresses HIF1α-independent VEGF expression and hepatocellular carcinoma angiogenesis. Br J Pharmacol. 2020 Mar 6. (IF:7.730)
  45. Guo W, Tan HY, Chen F, Wang N, Feng Y*. Targeting Cancer Metabolism to Resensitize Chemotherapy: Potential Development of Cancer Chemosensitizers from Traditional Chinese Medicines. Cancers (Basel). 2020;12(2). pii: E404. (IF:6.126)
  46. Huang J, Guo W, Cheung F, Tan HY, Wang N, Feng Y*. Integrating Network Pharmacology and Experimental Models to Investigate the Efficacy of Coptidis and Scutellaria Containing Huanglian Jiedu Decoction on Hepatocellular Carcinoma. Am J Chin Med. 2020;48(1):161-182. (IF:3.682)
  47. Guo W, Huang J, Wang N, Tan HY, Cheung F, Chen F, Feng Y*. Integrating Network Pharmacology and Pharmacological Evaluation for Deciphering the Action Mechanism of Herbal Formula Zuojin Pill in Suppressing Hepatocellular Carcinoma. Front Pharmacol. 2019;10:1185. (IF:4.235)
  48. Tan HY, Ho VW, Chan YT, Zhang C, Wang N, Xia W, Feng Y*. Combination of Gentiana rhodantha and Gerbera anandria in the BL02 formula as therapeutics to non-small cell lung carcinoma acting via Rap1/cdc42 signaling: A transcriptomics/ bio-informatics biological validation approach. Pharmacol Res. 2019;155:104415. (IF:5.893)
  49. Li S, Tan HY, Wang N, Feng Y, Wang X, Feng Y*. Recent Insights Into the Role of Immune Cells in Alcoholic Liver Disease. Front Immunol. 2019 Jun 12;10:1328. (IF:5.085)
  50. Hong M, Shi H, Wang N, Tan HY, Wang Q, Feng Y*. Dual Effects of Chinese Herbal Medicines on Angiogenesis in Cancer and Ischemic Stroke Treatments: Role of HIF-1 Network. Front Pharmacol. 2019 Jun 26;10:696. (IF:4.235)
  51. Fu B, Wang N, Tan HY, Li S, Cheung F, Feng Y*. Multi-Component Herbal Products in the Prevention and Treatment of Chemotherapy-Associated Toxicity and Side Effects: A Review on Experimental and Clinical Evidences. Front Pharmacol. 2018 Nov 29;9:1394. (IF: 4.235)
  52. Chen F, Wang N, Tan HY, Guo W, Zhang C, Feng Y*. The functional roles of exosomes-derived long non-coding RNA in human cancer. Cancer Biol Ther. 2019;20(5):583-592. (IF:3.659)
  53. Tan HY, Wang N, Lam W, Guo W, Feng Y*, Cheng YC*. Targeting tumour microenvironment by tyrosine kinase inhibitor. Mol Cancer. 2018;17(1):43. (IF:15.302)
  54. Li S, Tan HY, Wang N, Cheung F, Hong M, Feng Y*. The Potential and Action Mechanism of Polyphenols in the Treatment of Liver Diseases. Oxid Med Cell Longev. 2018; 4:8394818. (IF:5.076)
  55. Liu Y, Yang A, Qu Y, Wang Z, Zhang Y, Liu Y, Wang N, Teng L, Wang D*. Ameliorative effects of Antrodia cinnamomea polysaccharides against cyclophosphamide-induced immunosuppression related to Nrf2/HO-1 signaling in BALB/c mice. Int J Biol Macromol. 2018 Sep;116:8-15. (IF:5.162)
  56. Li S, Wang N, Tan HY, Hong M, Yuen MF, Li H, Feng Y*. Expansion of Granulocytic- Myeloid-derived Suppressor Cells in Response to Ethanol-Induced Acute Liver Damage. Front Immunol. 2018;9:1524. (IF: 5.085).
  57. Zhang C, Wang N, Xu Y, Li S, Tan HY, Feng Y*. Molecular Mechanisms involved in Oxidative Stress-Associated Liver Injury induced by Chinese Herbal Medicine: A Literature Review and Network Pharmacology Study. Int J Mol Sci. 2018 Sep 13;19(9). (IF: 4.556)
  58. Guo W, Tan HY, Wang N, Wang X, Feng Y*. Deciphering hepatocellular carcinoma through metabolomics: from biomarker discovery to therapy evaluation. Cancer Manag Res. 2018;11;10:715-734. (IF:2.886)
  59. Xu Y, Tan HY, Li S, Wang N, Feng Y*. Panax notoginseng for Inflammation-Related Chronic Diseases: A Review on the Modulations of Multiple Pathways. Am J Chin Med. 2018; 5:1-26. (IF:3.682)
  60. Cheng CS, Chen J, Tan HY, Wang N, Chen Z, Feng Y*. Scutellaria baicalensis and Cancer Treatment: Recent Progress and Perspectives in Biomedical and Clinical Studies. Am J Chin Med. 2018;46(1):25-54. (IF:3.682)
  61. Zhang C, Xu Y, Tan HY, Li S, Wang N, Zhang Y, Feng Y*. Neuroprotective effect of He-Ying-Qing-Re formula on retinal ganglion cell in diabetic retinopathy. J Ethnopharmacol. 2018;214:179-189. (IF:3.690)
  62. Li S, Wang N, Hong M, Tan HY, Pan G, Feng Y*. Hepatoprotective Effects of a Functional Formula of Three Chinese Medicinal Herbs: Experimental Evidence and Network Pharmacology-Based Identification of Mechanism of Action and Potential Bioactive Components. Molecules. 2018;23(2). pii: E352. (IF:3.267)
  63. Zhang C, Wang N, Tan HY, Guo W, Li S, Feng Y*. Targeting VEGF/VEGFRs Pathway in the Antiangiogenic Treatment of Human Cancers by Traditional Chinese Medicine. Integr Cancer Ther. 2018;1:1534735418775828. (IF:2.337)
  64. Tan HY, Wang N, Li S, Hong M, Guo W, Man K, Cheng CS, Chen Z, Feng Y*. Repression of WT1-Mediated LEF1 Transcription by Mangiferin Governs β-Catenin-Independent Wnt Signalling Inactivation in Hepatocellular Carcinoma. Cell Physiol Biochem. 2018; 28;47(5):1819-1834.
  65. Hong M, Li S, Wang N, Tan HY, Cheung F, Feng Y*. A Biomedical Investigation of the Hepatoprotective Effect of Radix salviae miltiorrhizae and Network Pharmacology-Based Prediction of the Active Compounds and Molecular Targets. Int J Mol Sci. 2017;18. pii: E620. (IF:4.556)
  66. Hong M, Zhang Y, Li S, Tan HY, Wang N, Mu S, Hao X, Feng Y*. A Network Pharmacology-Based Study on the Hepatoprotective Effect of Fructus Schisandrae. Molecules. 2017;22(10). pii: E1617. (IF:3.267)
  67. Hong M, Li S, Tan HY, Cheung F, Wang N, Huang J, Feng Y*. A Network-Based Pharmacology Study of the Herb-Induced Liver Injury Potential of Traditional Hepatoprotective Chinese Herbal Medicines. Molecules. 2017;22. pii: E632. (IF:3.267)
  68. Zhou Y, Guo Z, Meng Q, Lu J, Wang N, Liu H, Liang Q, Quan Y, Wang D*, Xie J*. Cordycepin Affects Multiple Apoptotic Pathways to Mediate Hepatocellular Carcinoma Cell Death. Anticancer Agents Med Chem. 2017;17:143-9. (IF:2.049)
  69. Huang J, Li L, Cheung F, Wang N, Li Y, Fan Z, Yin F, Yang J, Gao R, He Y, Feng Y*. Network Pharmacology-Based Approach to Investigate the Analgesic Efficacy and Molecular Targets of Xuangui Dropping Pill for Treating Primary Dysmenorrhea. Evid Based Complement Alternat Med. 2017;2017:7525179. (IF:1.813)
  70. Huang J, Cheung F, Tan HY, Hong M, Wang N, Yang J, Feng Y*, Zheng Q*. Identification of the active compounds and significant pathways of yinchenhao decoction based on network pharmacology. Mol Med Rep. 2017;16(4):4583-4592. (IF:2.100)
  71. Tan HY, Wang N, Li S, Hong M, Wang X, Feng Y*. The Reactive Oxygen Species in Macrophage Polarization: Reflecting Its Dual Role in Progression and Treatment of Human Diseases. Oxid Med Cell Longev. 2016;2016:2795090. (IF:5.085)
  72. Li S, Hong M, Tan HY, Wang N, Feng Y*. Insights into the Role and Interdependence of Oxidative Stress and Inflammation in Liver Diseases. Oxid Med Cell Longev. 2016;2016:4234061. (IF:5.085)
  73. Wang J, Song J, Wang D, Zhang N, Lu J, Meng Q, Zhou Y, Wang N, Liu Y, Wang D*, Teng L*. The anti-membranous glomerulonephritic activity of purified polysaccharides from Irpex lacteus Fr. Int J Biol Macromol. 2016;84:87-93. (IF:5.162)
  74. Tan HY, Wang N, Takahashi M, Feng Y, Li H, Feng Y*. New Natural Pigment Fraction Isolated from Saw Palmetto: Potential for Adjuvant Therapy of Hepatocellular Carcinoma. Int J Mol Sci. 2016;17. pii: E1277. (IF:4.556)
  75. Hong M, Tan HY, Li S, Cheung F, Wang N, Nagamatsu T, Feng Y*. Cancer Stem Cells: The Potential Targets of Chinese Medicines and Their Active Compounds. Int J Mol Sci. 2016;17. pii: E893. (IF: 4.556)
  76. Lam P, Cheung F, Tan HY, Wang N, Yuen MF, Feng Y*. Hepatoprotective Effects of Chinese Medicinal Herbs: A Focus on Anti-Inflammatory and Anti-Oxidative Activities. Int J Mol Sci. 2016;17(4):465. (IF: 4.556)
  77. Liu T, Wang N, Zhang L*, Zhong L*. Chinese Herbal Medicine for Functional Abdominal Pain Syndrome: From Clinical Findings to Basic Understandings. Evid Based Complement Alternat Med. 2016;2016:8652523. (IF:1.813)
  78. Li S, Tan HY, Wang N, Hong M, Li L, Cheung F, Feng Y*. Substitutes for Bear Bile for the Treatment of Liver Diseases: Research Progress and Future Perspective. Evid Based Complement Alternat Med. 2016;2016:4305074. (IF:1.813)
  79. Tan HY, San-Marina S, Wang N, Hong M, Li S, Li L, Cheung F, Wen XY, Feng Y*. Preclinical Models for Investigation of Herbal Medicines in Liver Diseases: Update and Perspective. Evid Based Complement Alternat Med. 2016;2016:4750163. (IF:1.813)
  80. Tan HY, Wang N, Tsao SW, Che CM, Yuen MF, Feng Y*. IRE1α inhibition by natural compound genipin on tumour associated macrophages reduces growth of hepatocellular carcinoma. Oncotarget. 2016;7:43792-804.
  81. Hong M, Wang N, Tan HY, Tsao SW, Feng Y*. MicroRNAs and Chinese Medicinal Herbs: New Possibilities in Cancer Therapy. Cancers (Basel). 2015;7:1643-57. (IF:6.162)
  82. Hong M, Li S, Tan HY, Wang N, Tsao SW, Feng Y*. Current Status of Herbal Medicines in Chronic Liver Disease Therapy: The Biological Effects, Molecular Targets and Future Prospects. Int J Mol Sci. 2015;16:28705-45. (IF:4.556)
  83. Li S, Tan HY, Wang N, Zhang ZJ, Lao L, Wong CW, Feng Y*. The Role of Oxidative Stress and Antioxidants in Liver Diseases. Int J Mol Sci. 2015;16:26087-124. (IF:4.556)
  84. Wang L, Wang N, Tan HY, Zhang Y, Feng Y*. Protective effect of a Chinese Medicine formula He-Ying-Qing-Re Formula on diabetic retinopathy. J Ethnopharmacol. 2015;169:295-304. (IF:3.690)
  85. Wang X, Wang N, Cheung F, Lao L, Li C, Feng Y*. Chinese medicines for prevention and treatment of human hepatocellular carcinoma: current progress on pharmacological actions and mechanisms. J Integr Med. 2015;13:142-64. (IF:2.446)
  86. Tan HY, Wang N, Tsao SW, Zhang Z, Feng Y*. Suppression of vascular endothelial growth factor via inactivation of eukaryotic elongation factor 2 by alkaloids in Coptidis rhizome in hepatocellular carcinoma. Integr Cancer Ther. 2014;13:425-34. (IF:2.370)
  87. Wang X, Feng Y*, Wang N, Cheung F, Tan HY, Zhong S, Li C, Kobayashi S. Chinese medicines induce cell death: the molecular and cellular mechanisms for cancer therapy. Biomed Res Int. 2014;2014:530342. (IF:2.276)
  88. Tian Y, Teng LR, Song JJ, Meng QF, Lu JH, Zhang WW, Wei K, Wang N, Wang D*, Teng LS*. Studies on the analgesic activities of Jia-Yuan-Qing pill and its safety evaluation in mice. Protoplasma. 2014; 251:1245-53. (IF:2.751)
  89. Cheung F, Wang X, Wang N, Yuen MF, Ziea TC, Tong Y, Wong VT, Feng Y*. Chinese Medicines as an Adjuvant Therapy for Unresectable Hepatocellular Carcinoma during Transarterial Chemoembolization: A Meta-Analysis of Randomized Controlled Trials. Evid Based Complement Alternat Med. 2013;2013:487919. (IF:1.813)
  90. Cheung F, Feng Y*, Wang N, Yuen MF, Tong Y, Wong VT. Effectiveness of Chinese herbal medicine in treating liver fibrosis: a systematic review and meta-analysis of randomized controlled trials. Chin Med. 2012;7:5. (IF:2.960)
  91. Wang XB, Feng Y*, Wang N, Cheung F, Wong CW. Recent progress on anti-liver fibrosis candidates in patents of herbal medicinal products. Recent Pat Food Nutr Agric.2012;4:91-106.
  92. Feng Y*, Wang N, Ye X, Li H, Feng Y, Cheung F, Nagamatsu T. Hepatoprotective effect and its possible mechanism of Coptidis rhizoma aqueous extract on carbon tetrachloride-induced chronic liver hepatotoxicity in rats. J Ethnopharmacol. 2011;138:683-90. (IF:3.690)
  93. Zhu M, Wang N, Tsao SW, Yuen MF, Feng Y, Wan TS, Man K, Feng Y*. Up-regulation of microRNAs, miR21 and miR23a in human liver cancer cells treated with Coptidis rhizoma aqueous extract. Exp Ther Med. 2011; 2:27-32. (IF:1.785)
  94. Feng Y*, Wang N, Zhu M, Feng Y, Li H, Tsao S. Recent progress on anticancer candidates in patents of herbal medicinal products. Recent Pat Food Nutr Agric. 2011; 3:30-48.
  95. Feng Y*, Siu KY, Ye X, Wang N, Yuen MF, Leung CH, Tong Y, Kobayashi S. Hepatoprotective effects of berberine on carbon tetrachloride-induced acute hepatotoxicity in rats. Chin Med. 2010;5:33. (IF:2.690)
  96. Tang J, Feng Y*, Tsao S, Wang N, Curtain R, Wang Y. Berberine and Coptidis rhizoma as novel antineoplastic agents: a review of traditional use and biomedical investigations. J Ethnopharmacol. 2009;126:5-17. (IF:3.690)
  97. Feng Y*, Siu K, Wang N, Ng KM, Tsao SW, Nagamatsu T, Tong Y. Bear bile: dilemma of traditional medicinal use and animal protection. J Ethnobiol Ethnomed. 2009; 5:2. (IF:2.264)
  98. Feng Y*, Cheung KF, Wang N, Liu P, Nagamatsu T, Tong Y. Chinese medicines as a resource for liver fibrosis treatment. Chin Med. 2009;4:16. (IF:2.690)
  99. Guan S, Su W*, Wang N, Li P, Wang Y. Effects of radix polygoni multiflori components on tyrosinase activity and melanogenesis. J Enzyme Inhib Med Chem. 2008; 23:252-5. (IF:4.310)
  100. Guan S, Su W*, Wang N, Li P, Wang Y. A potent tyrosinase activator from Radix Polygoni multiflori and its melanogenesis stimulatory effect in B16 melanoma cells. Phytother Res. 2008; 22:660-3. (IF:4.087)
B. Books and Book chapters
Books
  1. Associate Editor in Anticancer Chinese Medicines: Origen, chemistry, pharmacology and clinical application, Editor-in-Chief by Xu HX, Zhu GF, Feng Y. Science Publisher, Shanghai. 2016, Accepted for publication.
  2. Editorial Memberin Basic and Clinical Toxicology of Chinese Medicines, Editor-in-Chief by Feng Y. Commercial Press (HK) Ltd. 2009, pp394. (in Chinese).
  3. Chapter in book

  4. Chen F, Wang N, Feng Y. (2018). What Chinese Medicine can do for liver cancer?. In Liver Cancer, Ahmed Lasfar (Ed.), InTech (Accepted)
  5. Li S, Wang N, Feng YG, Li HY, Feng Y. (2018). Antioxidants In The Prevention And Treatment Of Liver Diseases. In Nutritional Antioxidant Therapies: Treatments and Perspectives, Al-Gubory, KH and Laher, I (Eds.), Springer-Verlag. DOI: 10.1007/978-3-319-67625-8_18.
  6. Guo W, Wang N and Feng Y (2017). Recent Progress on the Molecular Mechanisms of Anti-invasive and Metastatic Chinese Medicines for Cancer Therapy In Unique Aspects of Anti-cancer Drug Development, Dr. Jolanta Latosińska (Ed.), InTech, DOI: 10.5772/intechopen.69017.
  7. Hong M, Wang N and Feng Y (2016). Liver Cancer Treatment by Chinese Medicines and their Active Compounds, Anti-cancer Drugs - Nature, Synthesis and Cell, Dr. Jasna Bankovic (Ed.), InTech, DOI: 10.5772/65319.
  8. Feng Y, Li L, Li S, Wang N (2016). Study Liver Diseases, Chapter in TCM in Professional English for Traditional Chinese Medical Research (Tang Yao and Lao Lixing Editor in Chief). Beijing: People's Medical Publishing House. Accepted for publication. (In English. Textbook for postgraduate students).
  9. Wang N, Feng Y (2016). Quality Control of Chinese Herbal Medicine, Chapter in Professional English for Traditional Chinese Medical Research, Editor-in-Chief by Tong Y and Lao L. Beijing: People's Medical Publishing House. 2016, Accepted for publication. (In English. Textbook for postgraduate students).
  10. Wang N, Zhong L (2016). Summary of Advance of Chinese Medicine research in Hong Kong (2015), Chapter in Yearbook of Traditional Chinese Medicine of China. Beijing, China Press of Traditional Chinese Medicine, pp422-34.
  11. Zhang Y, Hong M, Li L, Wang N, Feng Y (2016). Classification of Chinese Herbal Medicine and its recent researches. Chapter in Traditional and Folk Herbal Medicine: Recent Researches -Vol.3 Editor: V.K. Gupta. Published by Daya Publishing House, A Division of Astral International Pvt. Ltd. New Delhi, India. 2016, p229-297.
  12. Tan H, Wang L, Cheung F, Wang N, Feng Y. (2016) Phytochemistry, Pharmacology and Therapeutics of Coptis: panacea for multiple diseases? Chapter in Medicinal Plants: Phytochemistry, Pharmacology and Therapeutics-Vol.4. Editor in Chief: V.K. Gupta. Published by Daya Publishing House, A Division of Astral International Pvt. Ltd. New Delhi, INDIA. 2016, p1-39.
  13. Hong M, Wang N and Feng Y (2015). The Role of Cell Autophagy in Cancer and Its Application in Drug Discovery, Cell Death - Autophagy, Apoptosis and Necrosis, Dr. Tobias Ntuli (Ed.), InTech, DOI: 10.5772/61780.
  14. Li L, Wang N, Feng Y. (2015) The Preventive and Therapeutic Effect of Coptidis Rhizoma and Berberine in Cancer. In Understand Cancer: Research and Treatment. iConcept Press. iConcept Press.
  15. Alan Worsley, Feng Y, Wang N, Ho Faith, Yu Edwin, Rose Mak. (2013) Use of Herbs in Chinese and Western Medicine. Hong Kong Museum of Medical Sciences Society. 1th edition in Bilingual in Chinese and English, Hong Kong, China. pp67.
  16. Feng YG, Wang N, Chueng F, Zhu M, Li H, Feng Y. Molecular and Cellular Mechanism Studies on Anticancer Effects of Chinese Medicines. (2011 Chapter in Biomedical Engineering, Trends, Research and Technologies / Book 3. pp644.
  17. Feng Y, Chen XM, Wang N and Shen JG. (2010) Current Progress on Medicinal Plants and their Biological Properties in Contemporary China. Chapter in Recent Progress in Medicinal Plants Vol. 28: Ethnomedicine: Source & Mechanism-II. Studium Press LLC, USA, pp491-546.
  18. Gene Atlas

  19. Feng Y, Tan HY, Wang N, Zhu M, Cheung F, Hong M. (2013) microRNA23a in Atlas of Genetics and Cytogenetics in Oncology and Haematology.
C. Conference Papers or Abstracts in Proceedings or Journals (reverse chronological order):

Overseas

  1. Wang N, Feng Y. The role of Autophagy protein 9b in liver carcinogenesis. The 25th Biennial Congress of the European Association for Cancer Research, Amsterdam, Netherland, June 30-July 3, 2018.
  2. Tan HY, Wang N, Feng Y. Genetical inhibition of IRE1α in macrophages suppresses hepatocellular carcinoma growth. The 25th Biennial Congress of the European Association for Cancer Research, Amsterdam, Netherland, June 30-July 3, 2018.
  3. Li S, Wang N, Feng Y. The Protective Role of Myeloid-derived Suppressor Cells in Acute Alcoholic Liver Injury. Poster presentation in Gordon Research Conferences: Alcohol-Induced End Organ Diseases, Ventura, CA, USA, March 26-31, 2017.
  4. Feng Y, Wang N. Drug Discovery from Chinese Medicines: What’s New in Next? 6th International Conference and Exhibition on Traditional & Alternative Medicine” (Traditional Medicine-2016), Amsterdam, Netherlands, September 14-16, 2016.
  5. Wang N, Feng Y. Exploring coptis and berberine as novel treatment for hepatocellular carcinoma targeting microRNAs. 15th Meeting of Consortium for Globalization of Chinese Medicine (CGCM), Academia Sinica, Taipei, August 23 - 25, 2016.
  6. Li S, Wang N, Feng Y. Anti-oxidative and anti-inflammatory effects of Chinese medicines in alcoholic liver models. 15th Meeting of Consortium for Globalization of Chinese Medicine (CGCM), Academia Sinica, Taipei, August 23 - 25, 2016.
  7. Tan HY, Wang N, Feng Y. Baicalin as a therapeutic candidate of macrophage reprogramming-mediated HCC tumor inhibition. 15th Meeting of Consortium for Globalization of Chinese Medicine (CGCM), Academia Sinica, Taipei, August 23 - 25, 2016.
  8. Li L, Cheung F, Wang N, Feng Y. An Experiential Teaching and Learning Module in Chinese Medicine: Field Trip. 15th Meeting of Consortium for Globalization of Chinese Medicine (CGCM), Academia Sinica, Taipei, August 23 - 25, 2016.
  9. Hong M, Wang N, Feng Y.  A Biomedical Investigation on the Hepatoprotective Effect of Coriolus versicolor L and Salvia miltiorrhiza Bge. The International Conference and Exhibition on Marine Drugs and Natural Products, Melbourne, Australia, July 25-27, 2016.
  10. Wang N, Feng Y. MicroRNAs mediate regulation of chemoresistance of hepatocellular carcinoma cells with involvement of p53 tumour suppressor. 24th Biennial Congress of the European Association for Cancer Research (EACR24), Manchester, UK. July 9-12, 2016.
  11. Tan HY, Wang N, Feng Y. Autophagy mediated activation of RelB/p52 responsible for the reprogramming of tumour associated macrophages. 24th Biennial Congress of the European Association for Cancer Research (EACR24), Manchester, UK. July 9-12, 2016.
  12. Feng Y, Wang N. Anticancer effect of coptis: Destination of its two thousand years journey? 2th international conference and exhibition on pharmacology and Ethnopharmacology, Chicago, USA, May 1-4, 2016.
  13. Feng Y, Wang N. Drug Discovery from Chinese Medicines: Opportunity and Challenge. 7th International Conference on Drug Discovery and Therapy (7th ICDDT), Sharjah, UAE, February 15th-18th, 2016.
  14. Feng Y, Wang N, Yuen MF. Breaking liver disease chain by Chinese medicines: evidences for preventing and treating hepatocellular carcinoma. Abstract Book 201, 14th Meeting of the Consortium for Globalization of Chinese Medicine (CGCM). London On, Canada. August 18-20, 2015.
  15. Wang N, Tan HY, Feng Y. Suppression of nascent protein synthesis by natural product berberine. 19th World Congress on Advances in Oncology & 17th International symposium on Molecular Medicine, Athens, Greece, October 9-11, 2014.
  16. Tan H, Wang N, Feng Y. Hepatoprotective effect of Coptidis rhizoma aqueous extract on liver fibrosis rat models. Abstract Book p217. 12th Meeting of the Consortium for Globalization of Chinese Medicine (CGCM). Graz, Austria. August 27-29, 2013.
  17. Wang N, Feng Y. The anti-metastatic effect of genipin, a natural product in Gardenia jasminoides Ellis on hepatocellular carcinoma and its underlying mechanism. Abstract Book p177. 12th Meeting of the Consortium for Globalization of Chinese Medicine (CGCM). Graz, Austria. August 27-29, 2013.
  18. Feng Y, Wang N, Cheung F, Wong Taam V, Xu Q. Modern scientific studies of Chinese herbal medicine treatment of renal diseases: challenges and opportunities. Abstract Book p69. 12th >Meeting of the Consortium for Globalization of Chinese Medicine (CGCM). Graz, Austria. August 27-29, 2013.
  19. Wang N, Feng Y. The anti-metastatic potential of Gegen Qinlian Decoction in human renal carcinoma and its underlying mechanism. Abstracts, 235. 11th Meeting of the Consortium for Globalization of Chinese Medicine (CGCM). Macau. August 21-23, 2012.
  20. Cheung F, Feng Y, Wang N, Yuen MF, Tong T, Wong Taam V. Efficacy of Chinese herbal medicine in treating liver fibrosis: a meta-analysis of 14 randomized controlled trials. Abstracts 54. 11th Meeting of the Consortium for Globalization of Chinese Medicine (CGCM). Macau. August 21-23, 2012.
  21. Feng Y, Wang N, Tong Y, Tsao SW. Berberine: an old drug but new use for liver diseases. International Congress on Natural Products Research (ICNPR 2012). Grand Hyatt New York, New York City, July 28- August 1, 2012.
  22. Feng Y, Wang N, Zhu M, Chow OY, Ng KM, Tong Y, Tsao S. Comparative study on bear bile and coptis . WCCM Handbook with programme 19. 8th world congress of Chinese Medicine. London. United Kingdom. September 2-3, 2011.
  23. Zhu M, Wang N, Tong Y, Tsao S, Feng Y. 3alpha,7beta-Dihydroxy-5beta-cholan -24-oic Acid N-(2-Sulfoethyl)amide alters the microRNAs expression and promotes cell migration of human hepatocellular carcinoma cells. International Journal of Cancer (Excellence in Oncology, 18-20 November 2010, Athens, Hilton, Greece), 128, Supplement 1, 39. (IF=7.360)
  24. Wang N, Zhu M, Tong Y, Tsao S, Feng Y. Tumor necrosis factor-α up-regulates the microRNA-21 expression and promotes cell migration in human hepatocellular carcinoma cells MHCC97-L. International Journal of Cancer (Excellence in Oncology, 18-20 November 2010, Athens, Hilton, Greece), 128, Supplement 1, 38. (IF=7.360)
  25. Feng Y, Wang N, Zhu MF, Zhang ZJ, Tong Y, Tsao SW. Interdisciplinary approaches in study of Chinese medicines: case of coptis. 15th World Congress on Advances in Oncology and 13th International Symposium on Molecular Medicine. October 7-9, 2010, Athens, Greece. International Journal of Molecular Medicine, V.26, supplement 1, 2010, p167.
  26. Wang N, Feng Y, Tang J, Tsao SW, Tong Y. The anti-tumor action of coptidis rhizome and its major compound berberine: ancient drug with novel use. 5th International Congress on Complementary and Alternative Medicine. Tromsø, Norway, May 19-21, 2010.
  27. Local

  28. Wang N, Feng Y. Investigating the translational potential of a traditional herbal formula TD in treating type II diabetes. 10th Pong Ding Yuen International Symposium on Traditional Chinese Medicine - Drug Discovery from Chinese Medicines: Strategies for Complicated Diseases in Hong Kong, December 1-3, 2017 (Plenary Speech)
  29. Tan HY, Wang N, Takahashi M, Feng Y. NYG, a novel pigmented fraction of Saw palmetto, suppresses tumour angiogenesis and progression of human hepatocellular carcinoma. 10th Pong Ding Yuen International Symposium on Traditional Chinese Medicine - Drug Discovery from Chinese Medicines: Strategies for Complicated Diseases in Hong Kong, December 1-3, 2017.
  30. Li S, Wang N, Feng Y. A Biomedical Investigation of the Hepatoprotective Effect of Jian-Gan-Bao and Network Pharmacology-Based Prediction of the Active Compounds and Molecular Targets. 10th Pong Ding Yuen International Symposium on Traditional Chinese Medicine - Drug Discovery from Chinese Medicines: Strategies for Complicated Diseases in Hong Kong, December 1-3, 2017.
  31. Tan HY, Wang N, Feng Y.  Genipin as an immune-modulator targeting at tumour associated macrophages mediated tumour regression. Awarded outstanding oral presentation. International postgraduate symposium in Chinese Medicine in Hong Kong, August 11, 2016.
  32. Wang N, Tan HY, Feng Y. Experimental Evidence of the Pharmacological Activity of Huanglian-Containing Chinese Medicine Formula in Treating Cancer. 14th International Conference & Exhibition of the modernization of Chinese Medicine & Natural Products (ICMCM conference 2015). Abstracts p.46. Hong Kong Convention and Exhibition Centre, Wan Chai, Hong Kong. August 13-14, 2015.
  33. Tan HY, Wang N, Feng Y. Inhibitory effect of Coptidis rhizoma aqueous extract in VEGF expression on hepatocellular carcinoma. 14th International Conference & Exhibition of the modernization of Chinese Medicine & Natural Products (ICMCM conference 2015). Abstracts p.45. Hong Kong Convention and Exhibition Centre, Wan Chai, Hong Kong. 13-14 August (Thursday-Friday), 2015.
  34. Tan HY, Wang N, Tsao SW, Zhang ZJ, Feng Y. Inhibitory effect of Coptidis rhizoma aqueous extract in VEGF expression on hepatocellular carcinoma. The 19th Research Postgraduate Symposium (RPS), Li Ka Shing Faculty of Hong Kong, The University of Hong Kong. December 10-11, 2014, Hong Kong.
  35. Feng Y, Wang N, Cheung F, Tan H, Hong M. Oxidative stress and antioxidative therapy in liver diseases. The 8th Pong Ding Yuen International Symposium on Traditional Chinese Medicine cum The 2nd International Chinese Symposium on Free Radical Research & The 6th Symposium for Three Districts of Cross-straits on Free Radical Research. November 15-16, 2014, Hong Kong.
  36. Wang L, Wang N, Feng Y, Zhang YJ. Protective Effects of QingGanLiShui Formula on Intraocular Pressure and Retinal Ganglion Cells of Rats with Ocular Hypertension. The 10th international postgraduate symposium on Chinese medicine. Program Book, p55. Hong Kong convention and exhibition centre N106-107, Hong Kong. August 15, 2014.
  37. Hong M, Wang N, Feng Y. Drug-resistance in cancer stem cells and the impact of Chinese medicine. The 10th international postgraduate symposium on Chinese medicine. Program Book, p58-59. Hong Kong convention and exhibition center N106-107, Hong Kong. August 15, 2014.
  38. Li L, Ng CY, Wang N, Cheung F, Wang L, Zhang ZJ, Lao L, Iain Doherty, Feng Y. A New Teaching and Learning Module of Chinese Medicine On-site Field Trip Combing with Moodle E-learning Platform. The 10th international postgraduate symposium on Chinese medicine. Program Book, p127. Hong Kong convention and exhibition center N106-107, Hong Kong. August 15, 2014.
  39. Feng Y, Wang N, Tsao SW, Man M, Yuen MF, Che CM. Anti-liver cancer effect and the mechanism of Chinese medicines: from traditional use to scientific exploration. The Joint-Chairman of the Conference organizing committee. 12th International Conference & Exhibition of the modernization of Chinese Medicine & Natural Products. Hong Kong Convention and Exhibition Centre, Wan Chai, Hong Kong. 15-16 August (Thursday-Friday), 2013.
  40. Cheung F, Wang X, Wang N, Yuen MF, Ziea TC, Tong Y, Wong VT, Feng Y. Efficacy of Chinese medicines plus transarterial chemoembolization on intermediate or advanced hepatocellular carcinoma: a systematic review and meta-analysis of randomized controlled trials. 20th Hong Kong International Cancer Congress, 14- 15 November 2013, The Hong Kong Academy of Medicine, 99 Wong Chuk Hang Road, Hong Kong.
  41. Wang N, Feng Y. Differential inhibitory effect of berberine on human hepatocellular carcinoma. Programme book 84. The 8th international postgraduate symposium on Chinese medicine. Hong Kong convention and exhibition center N106-107, Hong Kong. August 16, 2012.
  42. Feng Y, Wang N, Zhu M, Chow O, Ng K, Tong Y, Tsao S. Comparative study on anti-cancer and anti-liver fibrosis between bear bile and botanic Chinese medicines. Book of Abstracts, p.45. 2010 international conference on integrate medicine against cancer cum 6th Pong Ding Yuen international symposium on traditional Chinese Medicine. November 26-28, 2010. HKU, Hong Kong.
  43. Wang N, Tsao SW, Tong Y, Feng Y. A Novel Mechanism Involved in the Degradation of Cyclin D1Induced by Berberine in Human Hepatocellular Carcinoma Cells. Oral Presentation. The 15th Research Postgraduate Symposium (RPS), Li Ka Shing Faculty of Medicine, The University of Hong Kong. December 10-11, 2010, Hong Kong.
  44. Wang N, Zhu M, Tong Y, Tsao S, Feng Y. Type1 and type2 cell death on anti-tumor effect of berberine in liver cancer cells. 9th Meeting of the Consortium for Globalization of Chinese Medicine (CGCM). Hong Kong. August 26-28, 2010. Abstract Book, p76.
  45. Wang N, Li PB, Su WW, Feng Y. Hepatoprotective effect of Hypericum japonicum extract and its fractions. 2009 Hong Kong-Macau postgraduate Symposium on Chinese Medicine. 99. August 13, 2009. Hong Kong.
  46. Mainland China

  47. Wang N, Xu Q, Feng Y. Berberine suppresses fibrogenesis of liver via targeting hepatic stellate cells. 16th Meeting of Consortium for Globalization of Chinese Medicine (CGCM). Guangzhou, China. August 18-20, 2017.
  48. Wang XB, Wang N, Li HL, Liu M, Cao FJ, Yu XJ, Zhang JX, Tan Y, Xiang LC, Feng Y.  Berberine suppresses invasion and migration of hepatocellular carcinoma cells by altering expression of PAI-1 and uPA. National annual conference for pharmacology of Chinese Medicine. Changsha, China. October 19, 2016.
  49. Feng Y, Wang N. Liver cancer treated by Chinese herbal medicines: miRNA as its target. BIT's 7th World DNA and Genome Day (WDD-2016), Dalian, China. April 25-28 2016.
  50. Feng Y, Wang N, Cheung F, Tan HY, Hong M, Li L, Li S. Frontier technology in drug discovery: case of coptis in prevention and treatment of liver diseases. Inaugural Conference of the Specialty Committee on Immunology of Traditional Chinese Medicine of the World Federation of Chinese Medicine Societies cum the First Annual Meeting, Guangzhou, China, November 21-22, 2014.
  51. Tan HY, Wang N, Feng Y. Perspective future of immuno-modulatory Chinese Medicines in treating cancer: The role of tumor associated macrophage. Inaugural Conference of the Specialty Committee on Immunology of Traditional Chinese Medicine of the World Federation of Chinese Medicine Societies cum the First Annual Meeting, Guangzhou, China, November 21-22, 2014.
  52. Wang N, Feng Y. Immune microenvironment of tumour: novel therapeutic target of Traditional Chinese Medicine. Inaugural Conference of the Specialty Committee on Immunology of Traditional Chinese Medicine of the World Federation of Chinese Medicine Societies cum the First Annual Meeting, Guangzhou, China, November 21-22, 2014.
  53. Wang N, Feng Y. p53-inducible microRNA-23a is regulated by berberine, a natural compound isolated from Rhizome Coptidis, in human hepatocellular carcinoma. Abstract Book 263 13th Meeting of the Consortium for Globalization of Chinese Medicine (CGCM). Beijing, P.R. China. August 27-29, 2014 .
  54. Feng Y, Wang N, Tan H, Hong M. MicroRNAs and Coptis: new exploration in cancer therapy. Abstract Book 032. 13th Meeting of the Consortium for Globalization of Chinese Medicine (CGCM). Beijing, P.R. China. August 27-29, 2014.
  55. Tan H, Wang N, Tsao SW, Zhang ZJ, Feng Y. Inhibition of tumor neovascularization by Coptidis rhizoma aqueous extract via eEF2 pathway. Abstract Book 262. 13th Meeting of the Consortium for Globalization of Chinese Medicine (CGCM). Beijing, P.R. China. August 27-29, 2014.
  56. Liu YZ, Wang N, Luo HY, Liang G, Feng Y, Pan WD. Design and synthesis of tetrandrine derivatives as potential anti-hepatocellular carcinoma agents. The Third Sino-French Symposium on Pharmacy and the Promotion for Industrialization. Abstracts p61. Qingzhen, Guizhou Province, P.R. China. August 20-23, 2014.
  57. Wang N,Feng Y. Comparison on the Therapeutic Action of Coptis and Bear Bile on Experimental Liver Fibrosis. Poster presentation, awarded for best poster presentation. 4th World Congress on Bioavailability and Bioequivalence Pharmaceutical R & D Summit (BABE-2013). DoubleTree by Hilton Beijing, China. May 20-22, 2013.
  58. Zhu M, Wang N, Tsao SW, Feng Y. MiR-21 and miR-23a were altered by Coptidis Rhizoma Aqueous Extract in Human Liver Cancer Cells. Abstracts 62. 11th Meeting of the Consortium for Globalization of Chinese Medicine (CGCM). Shanghai. August 26-28, 2011.
  59. Wang N, Pan W, Zhu M, Zhanf M, Hao X, Liang G, Feng Y. Fangchinoline is a potential anti-cancer drug by inducing autophagic cell death in heaptocellular carcinoma cells. Abstracts 61. 11th Meeting of the Consortium for Globalization of Chinese Medicine (CGCM). Shanghai. August 26-28, 2011.
GRANTS, AWARDS AND PATENTS
A. Research Grants
    External
  1. PI: Development of training courses on the toxicity, safety and clinical application of Chinese Medicine for Chinese Medicine practitioners. Chinese Medicine Development Fund, HK$ 384,200. 01/04/2021-31/03/2022.
  2. PI: Survey, evalution and optimisation of the traditional herbal processing technique “Nine repeats of steaming and Sun-dring” for Chinese Medicine Rehmania glutinosoa, Polygonum multiflorum and Polygonatum sibiricum. Chinese Medicine Development Fund, HK$1,047,120. 01/06/2020-31/05/2022.
  3. PA: Investigation on the effect of berberine on the improvement of diabetic retinopathy in insulin-treated diabetic mellitus. 15162961. Health and Medical Research Fund, HK$821,448. 01/04/2018-31/03/2020.
  4. PI: Berberine suppresses nascent protein synthesis in hepatocellular carcinoma. National Natural Science Foundation of China-Science Fund for Young Scholars . CNY$230,000. 01/2014-12/2016.
  5. PI: Multitarget regulation of berberine on the tumour microenvironment of hepatocellular carcinoma. Shenzhen Basic Research Program. CNY$230,000. 01/2015-12/2016.
  6. Co-I: Inhibitory effect of the natural compound fangchinoline from Stephania tetrandra S. Moore on human liver cancer stem cells. RGC/GRF, HK$1,181,602. 12/2019-11/2022, PI: Dr. Feng Y.
  7. Co-I: Secondary development of classical Chinese Medicine Formula Huanglian Jiedu Decoction (HLJDD): HLJDD reducing chemotherapy-induced diarrhoea and improving chemotherapy response. ITF-Tier2. HK$1,194,684. 03/2017-02/2019, PI: Dr Feng Y.
  8. Co-I: Berberine suppresses metastasis and recurrence of hepatocellular carcinoma via targeting circulating tumour cells. Health and Medical Research Fund, HK$999,832. 04/2019-03/2021. PI: Dr Feng Y.
  9. Co-I: Evaluation of the pre-clinical efficacy of baicalin in reversing hypoxia-induced sorafenib resistance in hepatocellular carcinoma. Health and Medical Research Fund, HK$94,800. 04/2019-09/2020. PI: Dr Tan HY.
  10. Internal

  11. PI: The suppressive effect of carnosic acid on human hepatocellular carcinoma: Involvement of Fli1. Seed Fund for Basic Research for Resubmission of GRF/ECS Proposals. HK$40,000. 07/2017-11/2017.
  12. PI: Hepatic SBP2 expression alleviates acute and chronic liver injury caused by alcohol beverage via suppressing inflammasome activation in hepatocytes. Seed Fund for Basic Research. HK$44,320. 06/2017-12/2018.
  13. PI: The role of myeloid-derived suppressor cells in acute alcoholic liver disease. Seed Fund for Basic Research. HK$150,000. 06/2016-12/2017.
  14. PI: Inhibition of carcinogenesis by geniposide isolated from Chinese Medicinal herbs. Small Project Funding. HK$43,844. 06/2015-12/2016.
  15. PI: Establishment of Dual-Bioluminescent In Vivo Imaging of Autophagy in Orthotopical HCC-Implanted Mice Model To Examine the Anti-Tumor Effect of Chinese Medicine. Small Project Funding. HK$38,560. 06/2013-12/2014.
  16. Co-I: Inhibitory effect of natural compound fangchinoline from Stephania tetrandra S. Moore on human liver cancer stem cells. Seed Fund for Basic Research for Resubmission of GRF/ECS Proposals. HK$40,000. 07/2017-11/2017, PI: Dr Feng Y.
  17. Co-I: Development of a Diversified Moodle-Based E-Chinese Medicine Question Bank for Enhancing Teaching Effectiveness and Student Learning Outcome: A Pilot Study. Teaching Development Grant (TDG). HK$249,965. 08/2017-01/2019, PI: Dr Feng Y.
  18. Co-I: Metabolomic study to reveal the mechanism underlying the anti-tumor activity of Chinese Medicine formula Zuo-Jin Wan on human hepatocellular carcinoma (HCC). Seed Fund for Basic Research. HK$59,490. 06/2017-06/2019, PI: Dr Feng Y.
  19. Co-I: Identification of the anti-tumour activity of a novel natural product derived-Histone Deacetylase inhibitor ZG01 on human hepatocellular carcinoma. Seed Fund for Basic Research. HK$68,980. 04/2016-03/2018, PI: Dr Feng Y.
  20. Co-I: Reprogramming of tumour associated macrophages by baicalin through autophagy mediated IKK-alpha dependent pathway. Seed Fund for Basic Research. HK$56,625. 06/2015-05/2017, PI: Dr Feng Y.
  21. Co-I: The inhibitory effect of berberine on tumour associated macrophages in HCC tumour microenvironment. Small Project Funding. HK$72,760. 04/2014-04/2016, PI: Dr Feng Y.
  22. Co-I: Exploring the mechanism underlying the anti-invasion effect of Chinese Medicine Formula Gegen Qinlian Decoction in Human Renal Carcinoma. Seed Fund for Basic Research. HK$67,300. 06/2013-05/2015, PI: Dr Feng Y.
  23. Co-I: An Improved Teaching and Learning Module of Chinese Medicine On-site Field Trip Combining with On-line Moodle for the new curriculum for double cohort BChinMed students and beyond. Teaching Development Grant (TDG), HK$276,000. 08/2013-01/2015, PI: Dr Feng Y.
  24. Contract Research

  25. Co-I:  Evaluation and therapeutic target identification of an anti-cancer herbal formula BL02. Guizhou Bailing Group Pharmaceutical Co., Ltd. CNY$2,000,000. 04/2016-03/2018, PI: Dr Feng Y.
  26. Co-I: Evaluation and mechanism study on the therapeutic effect of Tang-Ning-Tong-Luo Capsule on diabetic mellitus and its complications. Guizhou Bailing Group Pharmaceutical Co., Ltd. CNY$1,500,000, 02/2014-02/2016, PI: Dr Feng Y.
B. Awards
  1. University of Hong Kong/China Medical Board Grant, support for research training at King's College London, United Kingdom, HK$52,896, 2014.
  2. The best poster presentation awarded for Wang N,Feng Y for “Comparison on the Therapeutic Action of coptis and Bear Bile on Experimental Liver Fibrosis” in 4th World Congress on Bioavailability and Bioequivalence Pharmaceutical R&D Summit (BABE-2013). DoubleTree by Hilton, Beijing, China, 2013.
  3. YS and Christabel Lung Postgraduate Scholarship, HK$21,400, Hong Kong, 2011.
  4. University Postgraduate Fellowship by The University of Hong Kong, HK$70,000, Hong Kong, 2008.
C. Patents

    International

  1. Pan WD, Feng Y, Liu YZ, Wang N, Huang L, Liang GY, Zhang MS, Li TL, Lou HY.  Title: Design and synthesis of derivatives from benylisoquinoline alkaloids, PCT patent on file at 2015; US patent on file at 2017.
  2. Mainland China

  3. Feng Y,Wang N,Xia W. New application of a Chinese medicine formula,the patent office of the People's Republic of China, filed on September 14, 2018, Ref No.: CN108524627A.
  4. Feng Y, Wang N. Preparation and application of a Chinese medicine product to prevent and treated diabetic retinopathy,the patent office of the People's Republic of China, filed on January 16, 2018, Ref No.: CN107583003A.
  5. Pan WD, Feng Y, Liu YZ, Wang N, Huang L, Liang GY, Zhang MS, Li TL, Lou HY, Hu ZX, Liu S, Cao PX, Ruan JH. Design and synthesis of derivatives from benylisoquinoline alkaloids and its application in the prevention and treatment of liver diseases,the patent office of the People's Republic of China, filed on September 26, 2017, Ref No.: CN107207524A.
  6. Feng Y, Wang N. New Application of total alkaloids of Coptidis Rhizoma. the patent office of the People's Republic of China, awarded on March 5, 2014. Ref No.: CN102342984B。